Ivabradine, heart failure and chronic kidney disease

Authors

  • Giovanni Barbera U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)
  • Alberto Santoboni U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)
  • Antonio De Pascalis U.O.C. Nefrologia, Dialisi e Trapianto, Ospedale V. Fazzi, Lecce
  • Rodolfo Rivera U.O.C. Clinica Nefrologica, Ospedale S. Gerardo, Monza (MB)
  • Fulvio Floccari U.O.C. Nefrologia e Dialisi, Ospedale S. Paolo, Civitavecchia (RM)
  • Claudio Ronco International Renal Research Institute, Ospedale S. Bortolo, Vicenza
  • Luca Di Lullo U.O.C. Nefrologia e Dialisi, Ospedale L. Parodi-Delfino, Colleferro (RM)

DOI:

https://doi.org/10.33393/gcnd.2015.808

Keywords:

Heart failure, Comorbidities, Ivabradine, SHIFT trial, Morbidity, Mortality, Hospitalizations, Ventricular remodelling, Beta-blockers

Abstract

Ivabradine, heart failure and chronic kidney disease Incidence and prevalence of congestive heart failure are raising, especially in western countries. In Europe and in the United States it represents a disabling clinical disease for all injured people and it's accountable for the increase of hospitalization and sanitary costs. European guidelines have underlined the importance of the optimization of pharmacological treatment to improve both patients' outcomes and quality of life. SHIFT trial's results, based on the evaluation of ivabradine's efficacy if added to conventional congestive heart failure's therapy, seem to proceed in that direction. (Cardionephrology)

Downloads

Download data is not yet available.

Published

2015-06-05

How to Cite

Barbera, G., Santoboni, A., De Pascalis, A., Rivera, R., Floccari, F., Ronco, C., & Di Lullo, L. (2015). Ivabradine, heart failure and chronic kidney disease. Giornale Di Clinica Nefrologica E Dialisi, 27(2), 119–124. https://doi.org/10.33393/gcnd.2015.808

Issue

Section

Cardionephrology

Metrics